文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性黑色素瘤免疫检查点治疗前后白细胞介素-2 PET显像

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-02

该先导研究对转移性黑色素瘤患者静脉注射约200 MBq [18F]FB-IL2后行PET/CT,于免疫检查点抑制剂治疗前及治疗中评估IL-2R显像可行性;13例完成基线扫描,11例完成系列扫描,肿瘤摄取中位数自基线1.8降至治疗中1.7(p=0.043),但摄取变化与疗效不相关,未见[18F]FB-IL2相关不良反应。

要点

  • [18F]FB-IL2 PET安全可行,可用于IL-2R显像。
  • 治疗中肿瘤[18F]FB-IL2摄取较基线小幅下降(p=0.043)。
  • 该小样本中系列显像未检出治疗相关免疫应答,摄取变化与疗效不相关。

核心结论

  • [18F]FB-IL2 PET显像安全可行,但在这小样本中系列显像未检出治疗相关免疫应答。

研究设计与样本

  • 先导研究:转移性黑色素瘤患者静脉注射约200 MBq [18F]FB-IL2后行PET/CT,于免疫检查点抑制剂治疗前及治疗中扫描,并以RECIST v1.1评估疗效、对存档肿瘤组织行T细胞浸润免疫组化分析。
  • 基线扫描13例;11例完成系列显像(第6周3例、第2周7例、第4周1例);存档肿瘤组织4例用于免疫组化分析。

主要发现

  • 基线SUVmean以肾脏最高(14.2,IQR 11.6-18.0)、肝脏次之(10.6,IQR 8.6-13.4);淋巴组织中脾脏最高(10.9,IQR 8.8-12.4)、骨髓为2.5(IQR 2.1-3.0)。
  • 基线41个肿瘤病灶SUVmax为1.9(IQR 1.7-2.3)。
  • 治疗中肿瘤[18F]FB-IL2摄取中位数由基线1.8(IQR 1.7-2.1)降至1.7(IQR 1.4-2.1),p=0.043。
  • [18F]FB-IL2肿瘤摄取变化与疗效不相关;4例存档肿瘤组织IL-2R表达低,且与基线[18F]FB-IL2摄取不相关。
  • 未发生[18F]FB-IL2相关不良反应。

关键数值与推荐

  • 每例静脉注射约200 MBq [18F]FB-IL2后进行PET/CT扫描;健康组织摄取以SUVmean表示,肿瘤病灶以SUVmax表示。
  • 疗效评估采用RECIST v1.1;系列显像时间点为第2、4、6周。

临床怎么用

  • [18F]FB-IL2 PET可作为IL-2R显像的安全可行手段,但现有证据尚不支持用其系列显像早期判断免疫检查点抑制剂疗效。

局限性

  • 先导研究样本量小(基线13例、系列显像11例),系列显像时间点不统一,存档肿瘤组织仅4例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into treatment efficacy. Activated tumor-infiltrating T cells express the high-affinity interleukin-2 receptor (IL-2R). Therefore, we performed a pilot study, using fluorine-18-labeled IL-2 ([18F]FB-IL2 PET), to evaluate whether a treatment-induced immune response can be detected. METHODS: Patients with metastatic melanoma received ~ 200 MBq [18F]FB-IL2 intravenously, followed by a PET/CT scan before and during immune checkpoint inhibitor therapy. [18F]FB-IL2 uptake was measured as standardized uptake value in healthy tissues (SUVmean) and tumor lesions (SUVmax). Response to therapy was assessed using RECIST v1.1. Archival tumor tissues were used for immunohistochemical analyses of T cell infiltration. RESULTS: Baseline [18F]FB-IL2 PET scans were performed in 13 patients. SUVmean at baseline was highest in the kidneys (14.2, IQR: 11.6-18.0) and liver (10.6, IQR: 8.6-13.4). In lymphoid tissues, uptake was highest in spleen (10.9, IQR: 8.8-12.4) and bone marrow (2.5, IQR: 2.1-3.0). SUVmax in tumor lesions (n = 41) at baseline was 1.9 (IQR: 1.7-2.3). In 11 patients, serial imaging was performed, three at week 6, seven at week 2, and one at week 4. Median [18F]FB-IL2 tumor uptake decreased from 1.8 (IQR: 1.7-2.1) at baseline to 1.7 (IQR: 1.4-2.1) during treatment (p = 0.043). Changes in [18F]FB-IL2 tumor uptake did not correlate with response. IL-2R expression in four archival tumor tissues was low and did not correlate with baseline [18F]FB-IL2 uptake. No [18F]FB-IL2-related side effects occurred. CONCLUSION: PET imaging of the IL-2R, using [18F]FB-IL2, is safe and feasible. In this small patient group, serial [18F]FB-IL2-PET imaging did not detect a treatment-related immune response. TRIAL REGISTRATION: Clinicaltrials.gov : NCT02922283; EudraCT: 2014-003387.20.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van de Donk PP, Wind TT, Hooiveld-Noeken JS, et al. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging. 2021. PMID: 34076745. doi:10.1007/s00259-021-05407-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。